161 related articles for article (PubMed ID: 16417732)
21. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
22. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years.
Bili H; Laven J; Imani B; Eijkemans MJ; Fauser BC
Eur J Endocrinol; 2001 Dec; 145(6):749-55. PubMed ID: 11720900
[TBL] [Abstract][Full Text] [Related]
23. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Sahu A; Tripathy P; Mohanty J; Nagy A
J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.
Codner E; Soto N; Lopez P; Trejo L; Avila A; Eyzaguirre FC; Iniguez G; Cassorla F
J Clin Endocrinol Metab; 2006 Jun; 91(6):2250-6. PubMed ID: 16569737
[TBL] [Abstract][Full Text] [Related]
25. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial.
Banaszewska B; Pawelczyk L; Spaczynski RZ; Dziura J; Duleba AJ
J Clin Endocrinol Metab; 2007 Feb; 92(2):456-61. PubMed ID: 17105841
[TBL] [Abstract][Full Text] [Related]
26. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
28. Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome.
Bradbury RA; Lee P; Smith HC
Aust N Z J Obstet Gynaecol; 2017 Oct; 57(5):552-557. PubMed ID: 28597496
[TBL] [Abstract][Full Text] [Related]
29. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
30. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
[TBL] [Abstract][Full Text] [Related]
31. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
32. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
33. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial.
Moretti C; Guccione L; Di Giacinto P; Simonelli I; Exacoustos C; Toscano V; Motta C; De Leo V; Petraglia F; Lenzi A
J Clin Endocrinol Metab; 2018 Mar; 103(3):824-838. PubMed ID: 29211888
[TBL] [Abstract][Full Text] [Related]
34. Is the suppressive effect of cyproterone acetate on serum anti-Müllerian-hormone levels in women with polycystic ovary syndrome stronger than under oral contraceptive pill?
Plouvier P; Peigné M; Gronier H; Robin G; Catteau-Jonard S; Dewailly D
Gynecol Endocrinol; 2016 Aug; 32(8):612-616. PubMed ID: 26890873
[TBL] [Abstract][Full Text] [Related]
35. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
[TBL] [Abstract][Full Text] [Related]
36. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
[TBL] [Abstract][Full Text] [Related]
37. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Maier PS; Mattiello SS; Lages L; Spritzer PM
Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China.
Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W
J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857
[TBL] [Abstract][Full Text] [Related]
40. Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
Spritzer PM; Motta AB
Int J Clin Pract; 2015 Nov; 69(11):1236-46. PubMed ID: 26289303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
